Dasatinib for the Treatment of Moderate and Severe COVID-19

Summary

This phase II trial investigates how well dasatinib works in treating patients with moderate and severe COVID-19. Dasatinib is a drug used to treat chronic leukemia which may help reduce the strong inflammation caused by COVID-19 that can damage the lungs or other organs.

Timeline

Start

2022-08-05

Primary completion

2023-12-15

Completion

2024-12-15

Outcome

Outcome not reported

Stopped: “PI decided not to pursue study”

Drugs

Indications